The feasibility of MRI-based techniques for the evaluation of non-alcoholic fatty liver disease

Gachon University Gil Medical Center0 个研究点目标入组 20 人开始时间: 待定最近更新: 2020年7月13日

试验速览

暂无简介。

•Korean males aged 20 to under 40 at the time of screening
•Those who are over 50 kg and have a body mass index (kg per meter squared) of 18.5 or more and less than 28
•No congenital or chronic disease requiring treatment and no medical condition or findings as a result of medical examination
•A person who is determined to be suitable as a clinical test subject as a result of laboratory tests, such as a questionnaire and physical examination, serum test, hematology test, blood chemistry test and urine test
•A person who, after hearing and fully understanding the details of this clinical trial, voluntarily decided to participate and agrees in writing to follow the precautions

•Those whose AST and ALT exceed 2 times the upper limit of the normal range
•A person who is unable to handle the noise or isolation environment in the test equipment at the MRI laboratory or contraindicated for MRI examination
•Subjects diagnosed with alcoholic liver disease
•Other identified liver diseases: hepatitis B or C, autoimmune hepatitis, drug-induced liver damage, other liver diseases.
•Subjects with cirrhosis or biliary tract disease
•A history of taking medications that cause secondary fatty liver within the last year
•(corticosteroids, tamoxifen, amiodarone, methotrexate, etc.),
•Patients with diabetes
•Complications of diabetes/hypertension/other metabolic diseases or related diseases (ischemic heart disease, heart failure, chronic kidney disease stage =3)
•Persons deemed unsuitable due to other severe systemic diseases
•HIV-infected patients
•Pregnant women
•Drink more than 3 cups (approximately 30 g) daily within the last 10 years or drink more than 1 cup (approximately 10 g) daily within the last 1 year
•patients with overt proteinuria
•Patients with hypersensitivity or hypothyroidism/hypothyroidism
•A person who is determined to be unsuitable to participate in a clinical trial according to the judgment of the chief investigator and attending physician

发起方